XORTX Therapeutics Inc(XRTX)
$0.89+0.04 (+4.71%)
XRTX
XORTX Therapeutics Inc financials statements
$0.89
At close:+0.04 (+4.71%)
Want to see XRTX full AI Analyst Report?
XORTX Therapeutics Inc (XRTX) Ratios
83 Followers
XORTX Therapeutics Inc Ratios
XRTX's free cash flow for Q2 2026 was C$0.00. For the 2026 fiscal year, XRTX's free cash flow was increased by C$3.17M and operating cash flow was C$-3.17M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.61 | 3.53 | 13.80 | 7.21 | 28.78 |
| Quick Ratio | 1.61 | 3.53 | 13.80 | 7.21 | 28.78 |
| Cash Ratio | 1.44 | 3.26 | 11.69 | 6.90 | 26.89 |
| Solvency Ratio | -4.25 | -4.02 | -3.23 | -1.29 | -0.39 |
| Operating Cash Flow Ratio | -4.71 | -4.62 | -22.32 | -5.93 | -8.68 |
| Short-Term Operating Cash Flow Coverage | -75.69 | -90.35 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ 367.55K | C$ 1.92M | C$ 3.24M | C$ 5.52M | C$ 11.73M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.29 | 1.23 | 1.18 | 1.77 | 1.32 |
| Debt Service Coverage Ratio | -84.47 | -78.50 | 0.00 | 0.00 | -662.17 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -661.17 |
| Debt to Market Cap | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.34 | 0.01 | 0.05 | 0.00 |
| Net Debt to EBITDA | 0.26 | 0.80 | 0.53 | 1.10 | 5.12 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 73.68% | 100.00% |
| EBT Per EBIT | 81.58% | 80.45% | 59.51% | 76.29% | 56.92% |
| Return on Assets (ROA) | -99.17% | -77.08% | -52.29% | -56.48% | -9.51% |
| Return on Equity (ROE) | -127.67% | -94.59% | -61.60% | -99.89% | -12.51% |
| Return on Capital Employed (ROCE) | -156.49% | -117.57% | -92.89% | -114.46% | -17.25% |
| Return on Invested Capital (ROIC) | -153.74% | -116.22% | -92.68% | -113.77% | -17.25% |
| Return on Tangible Assets | -106.52% | -80.69% | -54.02% | -57.41% | -9.62% |
| Earnings Yield | -99.83% | -64.84% | -49.75% | -46.85% | -6.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 1.91 | 0.72 | 0.06 | 0.06 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -190.88 | -503.47 | -6274.11 | -6612.56 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 190.88 | 503.47 | 6274.11 | 6612.56 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.98 | -30.42 | -3.32 | -6.06 | -4.39 |
| Free Cash Flow Per Share | -2.98 | -30.42 | -3.35 | -6.09 | -4.42 |
| Dividend Paid and CapEx Coverage Ratio | -939063.33 | -89.97 | -141.99 | -196.13 | -150.94 |
| Capital Expenditure Coverage Ratio | -939063.33 | -89.97 | -141.99 | -196.13 | -150.94 |
| Operating Cash Flow Coverage Ratio | -75.69 | -90.35 | -571.95 | -115.51 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -105.87% | -71.99% | -115.36% | -60.39% | -19.63% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.00 | -1.54 | -2.01 | -2.13 | -14.90 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.28 | 1.46 | 1.24 | 2.13 | 1.86 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.94 | -1.39 | -0.87 | -1.66 | -5.09 |
| Price-to-Operating Cash Flow Ratio | -0.94 | -1.39 | -0.87 | -1.66 | -5.13 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.06 | 0.03 | -0.01 | 0.49 |
| Enterprise Value Multiple | -0.58 | -0.80 | -0.36 | -0.48 | -3.36 |
| Enterprise Value | 1.84M | 2.43M | 2.31M | 4.56M | 9.75M |
| EV to EBITDA | -0.58 | -0.80 | -0.36 | -0.48 | -3.36 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.65 | -0.69 | -0.35 | -0.51 | -2.02 |
| EV to Operating Cash Flow | -0.65 | -0.69 | -0.35 | -0.51 | -2.03 |
| Tangible Book Value Per Share | 2.00 | 27.37 | 2.25 | 4.59 | 11.88 |
| Shareholders’ Equity Per Share | 2.20 | 28.96 | 2.34 | 4.73 | 12.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.81 | -27.39 | -1.44 | -4.72 | -1.51 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.74 | 1.00 |
| Interest Burden | 0.82 | 1.00 | 0.44 | 1.00 | 0.57 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.04 | 1.11 | 3.05 | 1.16 | 3.04 |
Currency in CAD
